The cardiovascular safety of GLP-1 RAs, SGLT-2 inhibitors, and DPP-4 inhibitors has been investigated in RCTs that primarily included patients with established cardiovascular disease or with multiple risk factors [17, 22, 24, 32–34]. This evidence concerns the gene GLP1R and cardiovascular disorder.